CLDX
Celldex Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$39.68
+0.79%Aug 6, 2026, 00:00 UTC
Celldex Therapeutics reported its Q2 2026 financial results, with revenue of $22,000 and a net loss of $73.5 million.
Source:Jul 21, 2026, 20:01 UTC
Celldex reported Phase 2 study results for barzolvolimab in prurigo nodularis that did not meet primary and key secondary endpoints.
Jul 15, 2026, 20:01 UTC
Celldex announced that CFO Sam Martin plans to retire in 2027 and will remain in role through March 2027 to support transition.
Source:Jun 26, 2026, 00:00 UTC
Celldex Therapeutics, Inc. elected Harry H. Penner, Jr. as Chair of the Board, Anthony S. Marucci as Chief Executive Officer, and Keith L. Brownlie, Cheryl L. Cohen, and Herbert J. Conrad as Directors, effective June 25, 2026.